Rocket Pharmaceuticals

Rocket Pharmaceuticals

  • Founded: 2015
  • Location: Cranbury, NJ
  • Employee range: 50 - 200
  • Clinical stage: Clin2 (fast track)
  • Therapy area: Fanconi anemia (ODD)
  • Drug types: HEM, GEN, RAR, BON, IMM, CVV, MUS
  • Lead product: RP-L102
  • Product link:
  • Funding: $100M stock Oct 2022; $6.5M grant Apr 2019; $78M stock Apr 2019

job board

Short description:

Gene Therapies

Drug notes:

RP-L201 Clin2 (fast track) leukocyte adhesion deficiency-1 (ODD); RP-A501 Clin1 (fast track) Danon disease (ODD); RP-L301 Clin1 (fast track) pyruvate kinase deficiency (ODD); RP-A601 Clin0 PKP2-ACM (ODD, FT); BAG3 RD cardiovascular

Long description:

Rocket Pharmaceuticals is a clinical-stage company developing gene therapy treatments for rare childhood disorders. Life-threatening childhood disorders such as Fanconi Anemia, Danon Disease and Leukocyte Adhesion Deficiency are caused by genetic mutations in single genes. Rocket is developing therapies that directly target these mutations in affected cell types using both adeno-associated viral vectors and lentiviral vectors. Rocket’s state-of-the-art laboratories are built for designing, optimizing and advancing candidate therapeutics to clinical stage development.


© 2023 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy